349 related articles for article (PubMed ID: 33491759)
1. Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review).
Vivarelli S; Falzone L; Torino F; Scandurra G; Russo G; Bordonaro R; Pappalardo F; Spandidos DA; Raciti G; Libra M
Int J Oncol; 2021 Feb; 58(2):145-157. PubMed ID: 33491759
[TBL] [Abstract][Full Text] [Related]
2. Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.
Awadasseid A; Yin Q; Wu Y; Zhang W
Biomed Pharmacother; 2021 Oct; 142():111957. PubMed ID: 34339917
[TBL] [Abstract][Full Text] [Related]
3. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Dipasquale A; Persico P; Lorenzi E; Rahal D; Santoro A; Simonelli M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33574054
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
6. Current treatment strategies for COVID‑19 (Review).
Han F; Liu Y; Mo M; Chen J; Wang C; Yang Y; Wu J
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34664677
[TBL] [Abstract][Full Text] [Related]
7. Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review).
Shang J; Du L; Han N; Lv D; Wang J; Yang H; Bai L; Tang H
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576464
[TBL] [Abstract][Full Text] [Related]
8. Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.
Liu Y; Liu S; Qin Y; Zhao L; Li Y; Zhou C; Chen W
Int Immunopharmacol; 2021 Dec; 101(Pt A):108242. PubMed ID: 34688136
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19.
Mellinghoff SC; Vanshylla K; Dahlke C; Addo MM; Cornely OA; Klein F; Persigehl T; Rybniker J; Gruell H; Bröckelmann PJ
Front Immunol; 2021; 12():798276. PubMed ID: 34987520
[TBL] [Abstract][Full Text] [Related]
10. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
Yang Y; Xu G
Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
[TBL] [Abstract][Full Text] [Related]
14. Association of immune checkpoint inhibitors with SARS-CoV-2 infection rate and prognosis in patients with solid tumors: a systematic review and meta-analysis.
Sun L; Zhao F; Xiang Y; Chen S; Shu Q
Front Immunol; 2024; 15():1259112. PubMed ID: 38887296
[TBL] [Abstract][Full Text] [Related]
15. COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics.
Tworowski D; Gorohovski A; Mukherjee S; Carmi G; Levy E; Detroja R; Mukherjee SB; Frenkel-Morgenstern M
Nucleic Acids Res; 2021 Jan; 49(D1):D1113-D1121. PubMed ID: 33166390
[TBL] [Abstract][Full Text] [Related]
16. Approaches towards fighting the COVID‑19 pandemic (Review).
Tsai SC; Lu CC; Bau DT; Chiu YJ; Yen YT; Hsu YM; Fu CW; Kuo SC; Lo YS; Chiu HY; Juan YN; Tsai FJ; Yang JS
Int J Mol Med; 2021 Jan; 47(1):3-22. PubMed ID: 33236131
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
19. Possible effects of sirolimus treatment on the long‑term efficacy of COVID‑19 vaccination in patients with β‑thalassemia: A theoretical perspective.
Zurlo M; Nicoli F; Borgatti M; Finotti A; Gambari R
Int J Mol Med; 2022 Mar; 49(3):. PubMed ID: 35059731
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic.
Vlachakis D; Papakonstantinou E; Mitsis T; Pierouli K; Diakou I; Chrousos G; Bacopoulou F
Food Chem Toxicol; 2020 Dec; 146():111805. PubMed ID: 33038452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
